In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
21 authors.
Tomas PachanoResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.ORCID 0000-0003-2823-7715 He LengDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Ontario, Canada.
Guillaume DugiedDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Ontario, Canada.ORCID 0000-0003-0956-2010 Travis TribbleDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Ontario, Canada.
Vincent LoubiereResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.ORCID 0000-0002-3632-378X Yeojin LeeCentre for Molecular and Systems Biology, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Alexander SchleifferResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.ORCID 0000-0001-6251-2747 Veronika YoungInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.
Benjamin WellerInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.ORCID 0000-0002-0231-595X Eleanor A LyonsDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-0337-7140 Matthew R HassCenter for Autoimmune Genomics and Etiology, Division of Allergy & Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0001-9507-4333 Leah C KottayanCenter for Autoimmune Genomics and Etiology, Division of Allergy & Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0003-3979-2220 Matthew T WeirauchCenter for Autoimmune Genomics and Etiology, Division of Allergy & Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.ORCID 0000-0001-7977-9122 Juan I Fuxman BassBiology Department and Bioinformatics Program, Boston University, Boston, MA, USA.ORCID 0000-0001-9457-1207 Hayley J NewtonInfection Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-9240-2001 Alexander W EnsmingerDepartment of Molecular Genetics, University of Toronto, Ontario M5S 3E1, Canada.ORCID 0000-0003-0824-3704 Pascal Falter BraunInstitute of Network Biology (INET), Molecular Targets and Therapeutics Center (MTTC), Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany.ORCID 0000-0003-2012-6746 Alexander StarkResearch Institute of Molecular Pathology (IMP), Vienna Biocenter (VBC), Vienna, Austria.ORCID 0000-0003-2611-0841 Mikko TaipaleDonnelly Centre for Cellular and Biomolecular Research, University of Toronto, Ontario, Canada.ORCID 0000-0003-3811-1761 Funding
HLA GENE COMPLEMENTATION IN PRIMARY SJOGREN'S AND LUPUSR01AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KOTTYAN, LEAH CLAIRE, WEIRAUCH, MATTHEW TYSON · 1987 to 2025
$7.8MBinding of Epstein Barr Virus EBNA2 Unifies Multiple Sclerosis Genetic MechanismsR01NS099068 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI Leah Claire Kottyan, Matthew Tyson Weirauch · 2017 to 2026
$4.2MGenomics of Inflammatory Bowel DiseaseR01AI148276 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI KOTTYAN, LEAH CLAIRE · 2019 to 2023
$3.9MVirus-driven human gene misregulation in diseaseR01HG010730 · NHGRI · CINCINNATI CHILDRENS HOSP MED CTR · PI WEIRAUCH, MATTHEW TYSON · 2020 to 2023
$2.7MNHGRI NIH HHS R01 HG010730NIAID NIH HHS R01 AI024717NIAID NIH HHS R01 AI148276NINDS NIH HHS R01 NS099068
6 · The paper itselfAbstract
Pathogens deploy effector proteins to exploit host cell biology, and most pathogen open reading frames (ORFs) are rapidly evolving and lack functional annotation. We developed the eORFeome, a scalable functional genomics platform encompassing 3,835 effector ORFs from diverse viruses, bacteria, and parasites. High-throughput barcoded screens across NFκB, apoptosis, p53, cGAS-STING and MHC-I pathways revealed functions for hundreds of uncharacterized eORFs, unexpected new activities for known effectors, and distinct pathway-specific functions encoded by single ORFs. Illustrating the power of the approach, we identify HHV6A U14 as a p53 antagonist, HHV7 U21 as a dual-function STING antagonist and MHC-I antigen display inhibitor, and adenoviral 13.6K/i-leader protein as a
Identifiers
PMID41332698
PMCPMC12667889
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390